ClinicalTrials.gg

Program

anagliptin

Also written as “Anagliptin” and “SK-0403”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by 3 companies.

Furthest: phase 4, since Jan 21, 20266 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
JW Pharmaceutical31 open or runningphase 4since Jan 21, 2026Feb 6, 2012Mar 31, 2027phase 4 · NCT07442006
Kowa20 open or runningphase 2since Jul 22, 2010May 25, 2010none ahead
Sanwa Kagaku Kenkyusho10 open or runningphase 2since Sep 19, 2007Sep 19, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2007First study: phase 2 study in Diabetes Mellitus, Type 2New to Sanwa Kagaku KenkyushoSanwa Kagaku Kenkyusho · NCT00532506 · Japan
  2. May 25, 2010Kowa's first study: phase 1 study in Diabetes Mellitus, Type 2New to KowaKowa · NCT01131091 · 30 enrolled · United States
  3. Jul 22, 2010Phase 2 study in Diabetes Mellitus, Type 2Kowa · NCT01169090 · 620 enrolled · United States
  4. Feb 6, 2012JW Pharmaceutical's first studies: 2 phase 3 studies in Diabetes Mellitus, Type 2New to JW PharmaceuticalJW Pharmaceutical · NCT01529541, NCT01529528
  5. Jan 21, 2026Phase 4 study in Diabetes Mellitus, Type 2JW Pharmaceutical · NCT07442006 · 178 planned · South Korea

Ahead

  1. Mar 31, 2027Primary completion: phase 4 study in Diabetes Mellitus, Type 2JW Pharmaceutical · NCT07442006

TargetBeta

DPP4 →read by rule
“An orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
LinagliptinruleBoehringer Ingelheimphase 496
gemigliptinruleLG Chemphase 430
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07442006Diabetes Mellitus, Type 2 · South Korea4RecruitingJW PharmaceuticalMar 31, 2027178
NCT01529541Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedJW PharmaceuticalMay 2013200
NCT01529528Diabetes Mellitus, Type 2 · South Korea3CompletedJW PharmaceuticalSep 2012117
NCT01169090Diabetes Mellitus, Type 2 · United States2CompletedKowaJul 2011620
NCT01131091Diabetes Mellitus, Type 2 · United States1CompletedKowaNov 201030
NCT00532506Diabetes Mellitus, Type 2 · Japan2CompletedSanwa Kagaku Kenkyusho

How it is read

Names in the registry

  • “Anagliptin”, 4 entries
  • “SK-0403”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.